Fig. 3
Comparison of the mean slope (oxygen cost of PVA; a), mean VO2 intercept (PVA-independent VO2; b), mean VO2 consumed in E–C coupling (c), mean basal metabolic VO2 (d), mean ESP at mLVV (e), and mean CBF at mLVV (f) in the presence or absence of Cap or CPZ at 37 °C or 42 °C. Group data are mean ± SD. *p < 0.05 vs. 37 °C,†p < 0.05 vs. 42 °C. The mean slope and mean CBF did not change in Cap- or CPZ-treated hearts during 37 °C or 42 °C (a, f). The mean VO2 intercepts in Cap-treated hearts were significantly lower than that at 37 °C (b), which was due to the decrease in mean VO2 consumed in E–C coupling (c) without changing mean basal metabolic VO2 (d). The decrease in the mean VO2 for E–C coupling and the increase of mean basal metabolic VO2 in hyperthermia-hearts without changing mean VO2 intercepts was inhibited by CPZ-treatment (c, d). The mean ESP at mLVV in hyperthermia- and Cap-treated hearts were significantly lower than that during 37 °C (e). The decrease of mean ESP at mLVV in hyperthermia-hearts significantly inhibited by CPZ-treatment (e)